Crispr Therapeutics AG, the Healthcare sector company, was revisited by a Wall Street analyst on October 10. Analyst Alec Stranahan from Bank of America Securities maintained a Buy rating on the stock and has a $78.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alec Stranahan has given his Buy rating due to a combination of factors that highlight the potential of Crispr Therapeutics AG’s advancements in gene editing technology. The company’s entry into the alpha-1 antitrypsin deficiency (AATD) market with its CTX460 asset is particularly promising. Despite being behind competitors in trial initiation, Crispr’s approach may benefit from insights gained from others, potentially accelerating its development timeline. Preclinical data suggests that CTX460 could achieve higher serum AAT levels with lower doses compared to competitors, which could be a significant differentiator if confirmed in human trials.
Additionally, Crispr Therapeutics’ pipeline is showing strong potential, with multiple value-generating readouts expected soon. The company’s recent collaboration on the factor XI program and upcoming data presentations, such as the CTX310 data at the American Heart Association, further underscore the underappreciated value of its pipeline. These factors combined with the potential for a one-time therapy advantage over competitors contribute to the Buy rating and a price objective of $78.
Stranahan covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Agios Pharma, and Novavax. According to TipRanks, Stranahan has an average return of 1.4% and a 54.33% success rate on recommended stocks.